EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2 ‐ CAR ‐T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma

Yanyun Zhao, Peng Jiao iD, Zhuo Zhang, Yang Sun, Huiyan Sun, Xiaoguang Li, Zhixin Bie iD, Chenghua Xiao, Yanfei Qu, Wei Wang iD, Qinqin Xu, Lisheng Wang

Thoracic Cancer · 2026-04 · 17 (7)

DOI: 10.1111/1759-7714.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 29.03.2026. Verfasst von Yanyun Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Antigens, Neoplasm, Radiofrequency Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Qinghai Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung adenocarcinoma (LUAD) is highly relapsed and responds poorly to chimeric antigen receptor (CAR)‐T therapy due to antigenic heterogeneity and the immunosuppressive microenvironment. Trophoblast cell‐surface antigen 2 (TROP2), overexpressed in LUAD and linked to poor prognosis, is a promising target. Radiofrequency ablation (RFA) can cause direct tumor necrosis, trigger immunogenic cell death, and enhance immune infiltration through antigen secretion; however, it often fails to eradicate residual tumors. Therefore, combining RFA with CAR‐T‐cell therapy may offer a new and synergistic therapy against LUAD.

Objective

This study examined the cytotoxicity of TROP2‐directed CAR‐T cells against LUAD in vitro and observed their therapeutic efficacy and safety in combination with RFA in vivo.

Methods

Third‐generation TROP2‐CAR‐T cells were developed and characterized for transduction efficiency, CD4/CD8 ratio, and proliferative capacity. Their antigen‐specific cytotoxicity against TROP2 + target cells was observed using a luciferase‐based assay and cytokine analysis. An A549‐TROP2‐Luc xenograft model was developed to examine the therapeutic effects of RFA, TROP2‐CAR‐T monotherapy, and their combination. Tumor suppression, Ki67/TUNEL assays, and immunohistochemical (IHC) analyses were performed to evaluate efficacy and safety.

Results

TROP2‐CAR‐T cells showed efficient transduction and potent, antigen‐dependent cytotoxicity with significant cytokine secretion in vitro. In vivo, both RFA and TROP2‐CAR‐T therapy suppressed tumor growth, and their combination showed a synergistic antitumor effect without hepatic or renal toxicity.

Conclusion

The combination of RFA and TROP2‐CAR‐T therapy demonstrates enhanced antitumor efficacy and improved safety profile in LUAD, highlighting a promising combinatorial immunotherapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsAntigens, NeoplasmRadiofrequency AblationCell Adhesion MoleculesImmunotherapy, AdoptiveReceptors, Chimeric AntigenAnimalsHumansMiceXenograft Model Antitumor AssaysFemaleCombined Modality Therapy

Stichwörter der Autor:innen

TROP2‐CAR‐Timmunotherapylung adenocarcinomaradiofrequency ablationsafety profiles

Substanzen

Antigens, NeoplasmTACSTD2 protein, humanCell Adhesion MoleculesReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Qinghai Provincial People's Hospital, Xining, China.
  • Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • School of Nursing, Jilin University, Changchun, Jilin, China.
  • Laboratory of Molecular Diagnosis and Regenerative Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • The Sanly-Health Cell Technology Inc, Beijing, China.

ORCID-Profile: Peng Jiao, Zhixin Bie, Wei Wang

Förderung

  • Natural Science Foundation of Qinghai Province

Zitieren

APA

Zhao, Y., Jiao, P., Zhang, Z., Sun, Y., Sun, H., Li, X., Bie, Z., Xiao, C., Qu, Y., Wang, W., Xu, Q., & Wang, L. (2026). Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2 ‐ CAR ‐T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma. Thoracic Cancer, 17(7). https://doi.org/10.1111/1759-7714.70268

Vancouver

Zhao Y, Jiao P, Zhang Z, Sun Y, Sun H, Li X, et al. Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2 ‐ CAR ‐T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma. Thoracic Cancer. 2026;17(7). doi:10.1111/1759-7714.70268

BibTeX
@article{Zhao2026,
  author = {Zhao, Yanyun and Jiao, Peng and Zhang, Zhuo and Sun, Yang and Sun, Huiyan and Li, Xiaoguang and Bie, Zhixin and Xiao, Chenghua and Qu, Yanfei and Wang, Wei and Xu, Qinqin and Wang, Lisheng},
  title = {Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2 ‐ CAR ‐T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {7},
  doi = {10.1111/1759-7714.70268}
}
Kostenlos starten →